DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brucellosis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrucellosis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDoxycyclineApproved drug
Structures already discussed alongside brucellosis in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of Alpha1-antichymotrypsin variant DBS-I1: a drug-binding serpin for doxycycline — Doxycycline has a real, experimentally solved structure in complex with this target (PDB 5OM2, 1.47 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet dxtdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5OM2 · 1.47 Å · ligand Doxycycline (DXT). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 systematic review and meta-analysis of 30 randomised controlled trials (77 treatment arms) found that doxycycline-rifampicin led to significantly more overall failure than doxycycline-streptomycin, driven by a higher relapse rate (relative risk 2.80, 95% confidence interval 1.81 to 4.36; 13 trials, no heterogeneity). This held for patients with bacteraemia and complicated disease. Doxycycline-streptomycin itself had a significantly higher failure rate than a triple regimen of doxycycline-rifampicin-aminoglycoside (relative risk 2.50, 1.26 to 5.00; two trials). Gentamicin was not inferior to streptomycin (relative risk 1.45, 0.52 to 4.00 for failure; two trials). Quinolones combined with rifampicin were significantly less effective than doxycycline combined with rifampicin or streptomycin (relative risk 1.83, 1.11 to 3.02; five trials). Monotherapy carried a higher risk of failure than combination treatment given for similar duration (relative risk 2.56, 1.55 to 4.23; five trials). Treatment lasting six weeks or more was superior to shorter courses.
A 2005 review stated that currently recommended regimens had not been surpassed by newer compounds, but noted that large, multi-centre, multinational trials were absent, making adequate evaluation of various therapeutic strategies impossible. A 1992 report described a shift away from streptomycin plus tetracycline due to ineffectiveness and frequent relapses, recommending two- or three-drug combinations including quinolones or third-generation cephalosporins for at least six weeks. Two 2024 reviews (identical abstracts) reiterated that brucellosis treatment faces ongoing challenges and that emerging approaches require further research, but provided no new trial data.
A 2007 seroprevalence study in India tested 618 high-risk individuals (veterinarians, assistants, officers, supervisors, group D workers, shepherds, butchers) using indirect ELISA. Prevalence was 41.23% in veterinary inspectors, 30.92% in veterinary assistants, 12.37% in veterinary officers, 6.18% in veterinary supervisors, 6.18% in group D workers, 2.06% in shepherds, and 1.03% in butchers. The authors called for immediate control measures.
What remains missing are large, multi-centre, multinational randomised trials that can adequately compare modern regimens, particularly those including aminoglycosides, quinolones, and triple combinations. No trial has yet identified a regimen that reliably prevents relapse in complicated or bacteraemic disease without significant toxicity. Patient stratification by disease severity, duration of illness, and Brucella species is not supported by the existing evidence base. Funding for such trials, rather than further small studies or reviews, is the primary gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMJ · 2008 · 299 citations · open access
Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials
AbstractOBJECTIVES: To determine and quantify differences in efficacy between treatment regimens for brucellosis. DESIGN: Systematic review and meta-analysis of randomised controlled trials assessing different antibiotic regimens and durations of treatment for human brucellosis. DATA SOURCES: PubMed, CENTRAL, Lilacs, conference proceedings, and bibliographies with no restrictions on language, study year, or publication status. Review methods Search, application of inclusion and exclusion criteria, data extraction, and assessment of methodological quality independently performed in duplicate. Primary outcomes were relapse and overall failure resulting from primary failure or relapse. Relative risks with 95% confidence intervals were calculated and pooled with a fixed effect model. RESULTS: 30 trials and 77 treatment arms were included. Overall failure was significantly higher with doxycycline-rifampicin compared to doxycycline-streptomycin, mainly due to a higher rate of relapse (relative risk 2.80, 95% confidence interval 1.81 to 4.36; 13 trials, without heterogeneity). Results were consistent among patients with bacteraemia and complicated brucellosis. Doxycycline-streptomycin resulted in a significantly higher rate of failure than doxycycline-rifampicin-aminoglycoside (triple drug regimen) (2.50, 1.26 to 5.00; two trials). Gentamicin was not inferior to streptomycin (1.45, 0.52 to 4.00 for failure; two trials). Quinolones combined with rifampicin were significantly less effective than doxycycline combined with rifampicin or streptomycin (1.83, 1.11 to 3.02, for failure; five trials). Monotherapy was associated with a higher risk of failure than combined treatment when administered for a similar duration (2.56, 1.55 to 4.23; five trials). Treatment for six weeks or more offered an advantage over shorter treatment durations. CONCLUSIONS: There are significant differences in effectiveness between currently recommended treatment regimens for brucellosis. The preferred treatment should be with dual or triple regimens including an aminoglycoside.
Indian Journal of Medical Microbiology · 2007 · 62 citations · open access
<i>Brucellosis</i> in high risk group individuals
AbstractPURPOSE: The purpose of this study was to investigate the seroprevalence of brucellosis among high-risk group individuals, consisting of veterinarians and para-veterinarians, shepherds, butchers and animal owners. METHODS: The present work was carried out at Project Directorate on Animal Disease Monitoring and Surveillance, Bangalore, by using the recently developed indirect enzyme-linked immunosorbent assay (ELISA) for antibodies to Brucella abortus. RESULTS: The results were compared with the conventional serological tests, Rose Bengal plate test and standard tube agglutination test. The result showed that the indirect ELISA was more sensitive than the conventional tests. Of 618 tested, the disease of prevalence was at 41.23% in veterinary inspectors, 30.92% in veterinary assistants, 12.37% in veterinary officers, 6.18% in veterinary supervisors, 6.18% in Group D workers, 2.06% in shepherds and 1.03% in butchers. CONCLUSIONS: This study results highlight the immediate necessity to institute control measures to control Brucellosis.
Expert Opinion on Pharmacotherapy · 2005 · 59 citations
Effective treatments in the management of brucellosis
AbstractTreatment of uncomplicated brucellosis in humans utilises a variety of anti-biotic combinations, applied to a series of important pathogenetic and clinical parameters. The currently recommended treatment regimens have not been surpassed by newer compounds, and various therapeutic strategies utilising these compounds cannot be adequately evaluated due to the absence of large, multi-centre, multinational trials. The review focuses on the basic principles of brucellosis treatment, the properties of the various regimens used, the results of trials involving them, and the questions raised about the efficacy of these regimens in certain clinical situations.
Journal of Clinical and Experimental Investigations · 2012 · 2 citations · open access
Importance of nonspecific laboratory tests in Brucella diagnosis
AbstractObjectives: Brucella infection doesn’t have spesific clinical evidences, for this reason it can be confused with febrile diseases. In this study we aimed investigating the importance of diagnosis with nonspesific laboratory tests in brucellosis. Materials and methods: We retrospectively screened clinically compatible with brucellosis, standard tube agglutination (STA) and STA tests with coombs of patients sera which came to Uşak State Hospital Central Laboratory between December 2010-May 2011. As control group, we determined random 62 patients attended to the laboratory between December 2010-May 2011 with STA test results are negative and not diagnosed brucellosis. Results: C-reactive protein elevated in 54 patients (87.0%), ESR elevated in 44 patients (70.9%), AST elevated in 22 patients (35.4%), ALT elevated in 7 patients (11.2%), ferritin elevated in 19 patients (30.6%), 8 patients had anemia (12.9%) of patient group. In control group, 7 patients elevated CRP (11.2%), 10 patients elevated ESR (16.1%), 1 patient elevated AST (1.6%), 1 patient elevated ALT (1.6%), 6 patients had anemia (9.6%) and decrease in ferritin level wasn’t detected. Conclusion: We concluded statistically significant high level of CRP, ESR, ALT, AST and ferritin support the test results too beside the spesific brucellosis tests.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Comprehensive Review of Brucellosis Treatment: Efficacy, Challenges, and Future Perspectives
AbstractBrucellosis, a zoonotic disease caused by various Brucella species, continues to pose significant public health challenges worldwide. This review provides a comprehensive overview of the treatment strategies for brucellosis, focusing on the efficacy of different antimicrobial agents, challenges encountered in treatment, and emerging therapeutic approaches. Drawing upon a wide range of scientific literature, this review aims to consolidate current knowledge on brucellosis treatment and highlight potential future directions for research and clinical management.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Comprehensive Review of Brucellosis Treatment: Efficacy, Challenges, and Future Perspectives
AbstractBrucellosis, a zoonotic disease caused by various Brucella species, continues to pose significant public health challenges worldwide. This review provides a comprehensive overview of the treatment strategies for brucellosis, focusing on the efficacy of different antimicrobial agents, challenges encountered in treatment, and emerging therapeutic approaches. Drawing upon a wide range of scientific literature, this review aims to consolidate current knowledge on brucellosis treatment and highlight potential future directions for research and clinical management.
European Journal of Therapeutics · 1992 · 0 citations · open access
Changes in the Treatment of Brucellosis
AbstractTreatment of brucellosis has been changed because of the ineffectiveness of Streptomycin+ Tetracyclin combination and relapses seen frequently following this therapy. Many kinds of antibiotics and their combinations have been used in the treatment. Combinations with 2 or 3 antibiotics including quinolon antibiotics and 3 rd generation of cephalosporins have been recommended to use at least 6 weeks
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
